From intermediate AMD to geographic atrophy: Biomarkers, endpoints, and a roadmap for next-generation clinical trials

Authors:

Abstract
No abstract available
Funding Information
  • Carl Zeiss Meditec AG
  • Novartis

This publication has 233 references indexed in Scilit: